^
    over3years
    MyChoice CDx examines ovarian cancer tumors using two individual methods (BRCA1/2 mutation and genomic instability) to determine a patients HRD staus. ()
    Clinical
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    BRCA2 mutation • BRCA1 mutation
    |
    Myriad myChoice® CDx
    8years
    "Our research partners @myriadgenetics and @AstraZeneca are teaming up to use myChoice® HRD Plus to identify advanced #ovariancancer patients that can benefit from Lynparza and Avastin! #knowovarian https://t.co/oBKVRsxJTQ" (@NOCC_National)
    Clinical
    |
    Myriad myChoice® CDx
    |
    Avastin (bevacizumab) • Lynparza (olaparib)